Clinical Oncology
Volume 21, Issue 5 , Pages 401-407 , June 2009

Volumetric Modulated Arc Therapy and Conventional Intensity-modulated Radiotherapy for Simultaneous Maximal Intraprostatic Boost: a Planning Comparison Study

  • R. Shaffer

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
    • Corresponding Author InformationAuthor for correspondence: R. Shaffer, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6. Tel: +604-877-6000; Fax: +604-877-0505.
    • ,
  • W.J. Morris

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • V. Moiseenko

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • M. Welsh

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • C. Crumley

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • S. Nakano

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • M. Schmuland

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • T. Pickles

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    • ,
  • K. Otto

      Affiliations

    • British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6

Received 10 October 2008 ,Revised 30 December 2008 ,Accepted 22 January 2009.

References 

  1. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3–12
  2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  3. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74
  4. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;73:980–988
  5. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  6. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167:123–126
  7. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  8. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689
  9. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging. 2002;16:196–200
  10. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging. 2006;23:130–134
  11. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology. 1999;213:473–480
  12. Zelefsky MJ, Cohen G, Zakian KL, et al. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J. 2000;6:249–255
  13. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007;2:36
  14. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008;18:71–77
  15. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89:1800–1809
  16. Byar DP, Mostofi FK. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer. 1972;30:5–13
  17. De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000;47:639–648
  18. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35:310–317
  19. Palma D, Vollans E, James K, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:996–1001
  20. Otto K, Milette M, Wu J. Temporal delivery efficiency of a novel single gantry arc optimization technique for treatment of recurrent nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S703
  21. Cozzi L, Dinshaw KA, Shrivastava SK, et al. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 2008;89:180–191
  22. Morris W. ASCENDE-RT: androgen suppression combined with elective nodal and dose escalated radiation therapy. Available from: http://clinicaltrials.gov/show/NCT00175396
  23. Bucci J, Spadinger I, Hilts M, et al. Urethral and periurethral dosimetry in prostate brachytherapy: is there a convenient surrogate?. Int J Radiat Oncol Biol Phys. 2002;54:1235–1242
  24. Storchi PR, van Battum LJ, Woudstra E. Calculation of a pencil beam kernel from measured photon beam data. Phys Med Biol. 1999;44:2917–2928
  25. Stein J, Mohan R, Wang XH, et al. Number and orientations of beams in intensity-modulated radiation treatments. Med Phys. 1997;24:149–160
  26. Akimoto T, Katoh H, Noda SE, et al. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2005;63:472–478
  27. Thomas C, Keyes M, Liu M, Moravan V. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:447–455
  28. Lee WR. RTOG 0415 Trial: radiation therapy in treating patients with stage II prostate cancer. Available from: http://clinicaltrials.gov/show/NCT00175396
  29. van der Wielen GJ, Hoogeman MS, Dohle GR, van Putten WL, Incrocci L. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2008;71:795–800
  30. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol. 2007;84:107–113
  31. Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys. 2005;63:155–163
  32. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85:2630–2637
  33. Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology. 2000;55:382–386
  34. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7
  35. Willoughby TR, Kupelian PA, Pouliot J, et al. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;65:528–534

PII: S0936-6555(09)00045-4

doi: 10.1016/j.clon.2009.01.014

Clinical Oncology
Volume 21, Issue 5 , Pages 401-407 , June 2009

Article Tools

* Image Usage & Resolution